FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135673847> ?p ?o ?g. }

• W2135673847 endingPage "781" @default.
• W2135673847 startingPage "769" @default.
• W2135673847 abstract "Lung cancer accounts for the highest number of cancer-related deaths in the USA, highlighting the need for better prevention and therapy. Activation of the Nrf2 pathway detoxifies harmful insults and reduces oxidative stress, thus preventing carcinogenesis in various preclinical models. However, constitutive activation of the Nrf2 pathway has been detected in numerous cancers, which confers a survival advantage to tumor cells and a poor prognosis. In our study, we compared the effects of two clinically relevant classes of Nrf2 activators, dimethyl fumarate (DMF) and the synthetic oleanane triterpenoids, CDDO-imidazolide (CDDO-Im) and CDDO-methyl ester (CDDO-Me) in RAW 264.7 mouse macrophage-like cells, in VC1 lung cancer cells and in the A/J model of lung cancer. Although the triterpenoids and DMF both activated the Nrf2 pathway, CDDO-Im and CDDO-Me were markedly more potent than DMF. All of these drugs reduced the production of reactive oxygen species and inhibited nitric oxide production in RAW264.7 cells, but the triterpenoids were 100 times more potent than DMF in these assays. Microarray analysis revealed that only 52 of 99 Nrf2-target genes were induced by all three compounds, and each drug regulated a unique subset of Nrf2 genes. These drugs also altered the expression of other genes important in lung cancer independent of Nrf2. Although all three compounds enhanced the phosphorylation of CREB, only DMF increased the phosphorylation of Akt. CDDO-Me, at either 12.5 or 50mg/kg of diet, was the most effective drug in our lung cancer mouse model. Specifically, CDDO-Me significantly reduced the average tumor number, size and burden compared with the control group (P < 0.05). Additionally, 52% of the tumors in the control group were high-grade tumors compared with only 14% in the CDDO-Me group. Though less potent, CDDO-Im had similar activity as CDDO-Me. In contrast, 61–63% of the tumors in the DMF groups (400–1200mg/kg diet) were high-grade tumors compared with 52% for the controls (P < 0.05). Additionally, DMF significantly increased the average number of tumors compared with the controls (P < 0.05). Thus, in contrast to the triterpenoids, which effectively reduced pathogenesis in A/J mice, DMF enhanced the severity of lung carcinogenesis in these mice. Collectively, these results suggest that although CDDO-Im, CDDO-Me and DMF all activate the Nrf2 pathway, they target distinct genes and signaling pathways, resulting in opposite effects for the prevention of experimental lung cancer." @default.
• W2135673847 created "2016-06-24" @default.
• W2135673847 creator A5019578505 @default.
• W2135673847 creator A5020632716 @default.
• W2135673847 creator A5031341481 @default.
• W2135673847 creator A5031590940 @default.
• W2135673847 creator A5036700013 @default.
• W2135673847 creator A5047242587 @default.
• W2135673847 creator A5070774407 @default.
• W2135673847 date "2015-05-04" @default.
• W2135673847 modified "2023-10-03" @default.
• W2135673847 title "Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis" @default.
• W2135673847 cites W1482682744 @default.
• W2135673847 cites W1573437546 @default.
• W2135673847 cites W1577872659 @default.
• W2135673847 cites W1590241149 @default.
• W2135673847 cites W1900938706 @default.
• W2135673847 cites W1966133006 @default.
• W2135673847 cites W1969034373 @default.
• W2135673847 cites W1976949137 @default.
• W2135673847 cites W1977957483 @default.
• W2135673847 cites W1979124011 @default.
• W2135673847 cites W1986814178 @default.
• W2135673847 cites W1987669162 @default.
• W2135673847 cites W1989541636 @default.
• W2135673847 cites W1990488806 @default.
• W2135673847 cites W1992298869 @default.
• W2135673847 cites W1992724001 @default.
• W2135673847 cites W1998560601 @default.
• W2135673847 cites W2004029870 @default.
• W2135673847 cites W2016602233 @default.
• W2135673847 cites W2017498511 @default.
• W2135673847 cites W2027085316 @default.
• W2135673847 cites W2030180376 @default.
• W2135673847 cites W2030749349 @default.
• W2135673847 cites W2032424314 @default.
• W2135673847 cites W2034417993 @default.
• W2135673847 cites W2037106665 @default.
• W2135673847 cites W2038275783 @default.
• W2135673847 cites W2053492818 @default.
• W2135673847 cites W2057032167 @default.
• W2135673847 cites W2057721542 @default.
• W2135673847 cites W2058727371 @default.
• W2135673847 cites W2058792844 @default.
• W2135673847 cites W2078649420 @default.
• W2135673847 cites W2084472730 @default.
• W2135673847 cites W2087928294 @default.
• W2135673847 cites W2089655089 @default.
• W2135673847 cites W2099852670 @default.
• W2135673847 cites W2100850228 @default.
• W2135673847 cites W2108995381 @default.
• W2135673847 cites W2114438821 @default.
• W2135673847 cites W2116815663 @default.
• W2135673847 cites W2120742807 @default.
• W2135673847 cites W2122116064 @default.
• W2135673847 cites W2122884740 @default.
• W2135673847 cites W2123016486 @default.
• W2135673847 cites W2123253654 @default.
• W2135673847 cites W2125295686 @default.
• W2135673847 cites W2125851739 @default.
• W2135673847 cites W2129715920 @default.
• W2135673847 cites W2129726289 @default.
• W2135673847 cites W2130698201 @default.
• W2135673847 cites W2138271341 @default.
• W2135673847 cites W2138884788 @default.
• W2135673847 cites W2139101668 @default.
• W2135673847 cites W2140432305 @default.
• W2135673847 cites W2142449962 @default.
• W2135673847 cites W2143070168 @default.
• W2135673847 cites W2145158999 @default.
• W2135673847 cites W2145161910 @default.
• W2135673847 cites W2146492238 @default.
• W2135673847 cites W2148349695 @default.
• W2135673847 cites W2150926065 @default.
• W2135673847 cites W2152100400 @default.
• W2135673847 cites W2157829770 @default.
• W2135673847 cites W2158753973 @default.
• W2135673847 cites W2160886349 @default.
• W2135673847 cites W2161446823 @default.
• W2135673847 cites W2162420845 @default.
• W2135673847 cites W2164552211 @default.
• W2135673847 cites W2164949044 @default.
• W2135673847 cites W2165658124 @default.
• W2135673847 cites W2167191648 @default.
• W2135673847 cites W2169516568 @default.
• W2135673847 cites W2169961966 @default.
• W2135673847 cites W2301770039 @default.
• W2135673847 cites W2322165705 @default.
• W2135673847 doi "https://doi.org/10.1093/carcin/bgv061" @default.
• W2135673847 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4572919" @default.
• W2135673847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25939751" @default.
• W2135673847 hasPublicationYear "2015" @default.
• W2135673847 type Work @default.
• W2135673847 sameAs 2135673847 @default.
• W2135673847 citedByCount "57" @default.
• W2135673847 countsByYear W21356738472015 @default.
• W2135673847 countsByYear W21356738472016 @default.
• W2135673847 countsByYear W21356738472017 @default.

• next